Compare
Curanex Pharmaceuticals Inc vs Revelation Biosciences, Inc. vs NewcelX Ltd. vs PRF Technologies Ltd.
| Latest fiscal year | Curanex Pharmaceuticals Inc CURX | Revelation Biosciences, Inc. REVB | NewcelX Ltd. NCEL | PRF Technologies Ltd. PRFX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $17.0K |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | n/a | n/a | -311.8% (computed) |
| Operating margin | n/a | n/a | n/a | n/m |
| Net margin | n/a | n/a | n/a | n/m |
| Net income | -$4.23M | -$8.91M | -$8.30M | -$5.02M |
| EPS (Diluted) | -$0.17 | -$23.95 | $2.16 | -$7.47 |
| Operating cash flow | -$10.48M | -$8.27M | -$2.77M | -$3.96M |
| Free cash flow | n/a | n/a | -$2.77M | -$3.96M |
| Cash & equivalents | $5.00M | $10.70M | $2.20M | $3.12M |
| Total assets | $11.58M | $11.58M | $11.45M | $12.00M |
| Total liabilities | $361.0K | $2.72M | $4.20M | $2.71M |
| Shareholders' equity | $11.22M | $8.86M | $7.25M | $8.54M |
| Return on year-end equity | -37.7% | -100.6% | -114.5% | -58.8% |
| Shares outstanding | 28.34M | 1.58M | 4.80M | 830.6K |
Revenue, most recent five fiscal years
| Fiscal year | Curanex Pharmaceuticals Inc | Revelation Biosciences, Inc. | NewcelX Ltd. | PRF Technologies Ltd. |
|---|---|---|---|---|
| Latest | n/a | n/a | n/a | $17.0K Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | n/a | $0 Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | n/a | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | n/a |
| 4 years earlier | n/a | n/a | n/a | n/a |